MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
5.22
-0.13
-2.43%
After Hours: 5.32 +0.1 +1.91% 17:56 04/25 EDT
OPEN
5.27
PREV CLOSE
5.35
HIGH
5.27
LOW
5.11
VOLUME
1.54M
TURNOVER
0
52 WEEK HIGH
11.91
52 WEEK LOW
5.11
MARKET CAP
429.27M
P/E (TTM)
-2.5880
1D
5D
1M
3M
1Y
5Y
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Editas Medicine, Inc. Shares are down a considerable 25% in the last month. The company's share price has fallen 27% in a year. The stock has a price-to-sales ratio of 5.9x, compared to the industry average of 12.6x. Editas Medicine's revenue growth is expected to be lower than the rest of the industry in the coming years.
Simply Wall St · 2d ago
Editas Medicine To Present Pre-Clinical Data Demonstrating Progression Of In Vivo Medicines Pipeline At American Society Of Gene And Cell Therapy Annual Meeting
Editas Medicine presentations at ASGCT include oral presentation of in vivo pre-clinical data from mouse studies. Research on identifying potent large serine recombinases as a foundation to develop novel in vivo gene editing technologies for developing medicines. The company is developing an in-vivo gene editing technology.
Benzinga · 3d ago
Weekly Report: what happened at EDIT last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at EDIT last week (0408-0412)?
Weekly Report · 04/15 09:11
Weekly Report: what happened at EDIT last week (0401-0405)?
Weekly Report · 04/08 09:12
Shareholders in Editas Medicine (NASDAQ:EDIT) have lost 83%, as stock drops 9.4% this past week
Share price of Editas Medicine, Inc. Has dropped 26% in the last three months. The company's share price has declined 83% in three years. In the same period of time the company's revenue has shrunk by 34% per year. The firm is not profitable, and has lost 12% of its value over the last five years. We look at the fundamentals of the company to see if the stock is worth buying.
Simply Wall St · 04/06 12:19
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
Weekly Report: what happened at EDIT last week (0325-0329)?
Weekly Report · 04/01 09:12
More
About EDIT
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.